filmov
tv
Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program
Показать описание
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has decided to move its psychedelic DMT stroke program into a private company called Algernon NeuroScience.
Moreau telling Proactive AGN Neuro will stay private until it has advanced through to the completion of a Phase 2a stroke study in Q4 of the 2023. Following that, the company will consider a potential direct IPO listing onto the NASDAQ.
#proactiveinvestors #algernonpharmaceuticals #cse #otcqb
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Moreau telling Proactive AGN Neuro will stay private until it has advanced through to the completion of a Phase 2a stroke study in Q4 of the 2023. Following that, the company will consider a potential direct IPO listing onto the NASDAQ.
#proactiveinvestors #algernonpharmaceuticals #cse #otcqb
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
0:04:49
0:03:51
0:03:18
0:05:38
0:04:49
0:06:50
0:03:39
0:00:21
0:01:49
0:03:09
0:40:36
0:05:09
0:01:00
0:00:45
0:45:24
0:04:37
0:26:55
0:24:10
0:18:13
0:08:11
0:19:40
0:06:10
0:44:43
0:28:53